Multiple myeloma (MM) is characterized by accumulation of clonal plasma cells (PCs). CD45, a key regulator of antigenmediated signaling and activation in lymphocytes, is present in early stages of PCs development. We studied CD45 expression on MM PCs by flow cytometry, correlating it to important biological disease characteristics. Additionally, we examined the expression of various adhesion molecules on PCs. A total of 75 patients with untreated MM (29), relapsed MM (17), smoldering MM (12), and monoclonal gammopathy of undetermined significance (MGUS) (17) were studied. The proportion of PCs expressing CD45 was higher among those with early disease (MGUS or smoldering MM) compared to those with advanced disease (new or relapsed MM) (43 vs 22%; P ¼ 0.005). Among those with advanced disease, patients with bone lesions had a lower percentage of CD45-positive (CD45 þ ) PCs; 14 vs 34% (P ¼ 0.02). Patients with high-grade angiogenesis had a lower percentage of CD45 þ PCs; 13 vs 31% (P ¼ 0.03). The median overall survival for the CD45 þ group (420% PCs positive) was 39 vs 18 months for the CD45-negative (CD45À) group (P ¼ 0.07). The expression of CD138, CD56 and CD54 were higher among the CD45À PCs. This study demonstrates important biological correlates of CD45 expression on myeloma cells.
Introduction
Multiple myeloma (MM) is characterized by accumulation of malignant plasma cells (PCs) predominantly in the bone marrow, with tumor cells appearing in the circulation in significant numbers only in the late stages of the disease. During plasma cell development, there is progressive loss of B-cell markers like CD19, CD20 and CD45 and acquisition of markers such as CD138 and CD56, which are thought to characterize the malignant PCs in MM. CD45 was initially characterized as a leukocyte common antigen and can be found on all hematopoietic cells with exception of platelets and red blood cells. 1 It is a key regulator of antigen-mediated signaling and activation in B-and T lymphocytes. 2 CD45 expression has been the focus of considerable investigations in the context of MM and related disorders. [3] [4] [5] [6] [7] The role of CD45 in the biology of MM remains controversial. It has been shown to be predominantly present in the early stages of PC development, decreasing in expression with maturation. The expression of CD45 among the PCs in the bone marrow of patients with MM is heterogeneous. 3, 8 The weight of evidence suggests the presence of two populations of myeloma cells in the marrow; early PCs with CD45 expression and late PCs with dim or no expression. Important biological differences have been demonstrated between these two populations including their proliferative capability, IL-6 responsiveness and dependence, chromosomal abnormalities and angiogenic capability. The suggestion of prognostic value for CD45 expression on the myeloma cell 9 as well as recent studies suggesting that the clonal cell population in myeloma resides in the CD45 þ fraction of cells 10 indicate the relevance of CD45 biology in MM. Here, we prospectively studied the CD45 expression on bone marrow PCs of patients with different stages of MM, and compared it to important clinical and biological characteristics of this disease including clinical outcome, labeling index, bone marrow angiogenesis and bone disease. Additionally, we studied the differences in the expression of various adhesion molecules between these two subsets.
Methods and materials

Patients
All patients included in the study were seen in the Dysproteinemia Clinic, Mayo Clinic, Rochester between January 1995 and January 1996 and included patients with diagnosis of monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), or active multiple myeloma (MM). MGUS was defined by a serum M-protein concentration o3 g/dl; fewer than 10% plasma cells in the bone marrow, and absence of lytic lesions, anemia, hypercalcemia and/or renal insufficiency. Patients with serum monoclonal protein X3 g/dl or bone marrow plasma cells X10% without anemia, renal failure, hypercalcemia or lytic bone lesions were grouped as having SMM and those with any of these manifestations as active MM. Additional bone marrow was obtained, after informed consent, at the time of routine evaluation. The study was approved by the Institutional Review Board of the Mayo Foundation in accordance with the federal regulations and the Declaration of Helsinki. Clinical data regarding disease stage, presence of lytic bone lesions and follow-up data were obtained from patient records and the prospectively maintained institutional dysproteinemia database. Patients with MGUS and SMM were considered as having 'early disease' and those with newly diagnosed MM or relapsed MM were considered as having 'advanced disease' for the purpose of analysis.
Flow cytometry analysis
Plasma cells were identified by their characteristic strong CD38 expression. An additional marker for cytoplasmic light chain was used to confirm the clonality of the plasma cells. For this study, marrow monoclonal plasma cells were identified and the expression of various adhesion molecules were studied by threecolor flow cytometry as previously described. 11 Briefly, marrow aspirate was subjected to Ficoll-Paque to remove RBC. The cells to be analyzed for surface CD38, CD45 and cytoplasmic kappa or lambda were first incubated with phycoerythrin (PE)-conjugated anti-human CD38 (BD Biosciences, San Diego, CA, USA) and PerCP-conjugated anti-human CD45 (BD Biosciences, San Diego, CA, USA) for 15 min; then washed, fixed with 4 ml of lysolecithin (Sigma #L4129; 0.003% in 1% paraformaldehyde) solution and incubated for 30 min at 41 in the dark. After washing with 3 ml of PBS/3% BSA, the pellet was resuspended in 200 ml PBS/BSA and 100 ml added to each of two 12 Â 75 mm tubes. To these tubes either FITC-conjugated antihuman kappa or lambda light chain antibody (Biosource International, Camarillo, CA, USA) was added, and the suspension incubated for 30 min in the dark at 41C. After incubation, the cells were washed with 2 ml PBS, resuspended in 0.5 ml 1% paraformaldehyde, and analyzed on a FACScan flow cytometer. Cells that were CD38 þþ CD45À or the CD38 þþ CD45 dim and those that were CD38 þþ CD45 þ were gated and studied separately for the expression of the adhesion molecules. Patient samples with X20% of the plasma cells expressing CD45 were defined as CD45 positive ( Figure 1 ).
Labeling index
The bone marrow labeling index (LI) were performed as previously described. 12, 13 Briefly, the marrow sample was incubated with BrdU and cytospin slides were made. Slides are incubated with BU1 anti-BrdU monoclonal antibody followed by rhodamine isothiocyanate (RITC)-labeled anti-IgG antibody to detect BrdU; simultaneous staining with FITClabeled monospecific anti-kappa or anti-lambda antibodies identify light chain restricted cytoplasmic immunoglobulin positive (cIg þ ) plasma cells. The plasma cells are identified by their bright apple green (FITC) staining and the nucleus of cells in S-phase as bright orange-red (RITC) (Figure 1) . In total, 500 plasma cells are enumerated and the LI is calculated based on the number of cells showing nuclear BrdU uptake.
Microvessel staining and MVD determination
Paraffin-embedded bone marrow biopsy blocks, obtained at the same time as the marrow aspirates, were used for MVD determination. Immunohistochemical staining for CD34 was performed by a labeled streptavidin-biotin peroxidase method on the Ventana ES-automated immunohistochemistry stainer (Ventana Medical Systems, Tucson, AZ, USA) and bone marrow angiogenesis estimated by microscopic evaluation in terms of MVD, as previously described. [14] [15] [16] This technique has been evaluated in the past and found to be reproducible. Based on a visual estimate of the degree of staining for microvessels, the bone marrow specimens were graded as high or low grade. This visual grading system has been studied previously and correlates very well with those obtained by actual vessel counting. 15 
Statistical analysis
The w 2 and Fisher exact tests were used to compare differences among the patient groups for nominal variables and the student's t-test was used for comparing the continuous variables between the two groups. The differences in the expression of adhesion molecules between CD45 þ and CD45À cells were done using a paired t-test. Correlations between continuous variables were determined using the spearman rank correlation. Kaplan-Meier analysis was used for analyzing overall survival from the time of marrow examination with those alive at the last contact being censored at that time. Log rank test was used to compare the curves for statistical differences. A two-sided P-value of o0.05 was considered for determining significance.
Results
Bone marrows from 75 patients were studied for CD45 expression. These included 29 (39%) patients with newly diagnosed MM, 17 (23%) with relapsed MM, 12 (16%) with SMM and 17 (23%) with MGUS. The mean bone marrow plasma cell content by flow cytometry was 22% (median, 14%; range, 0.2-91%). In all, 30% of plasma cells expressed CD45 by flow cytometry (median, 14%; range, 0.1-100%). Among all patients, 44% (33/75) had more than 20% of plasma cells expressing CD45 and were categorized as the CD45 þ group. There was a progressive decrease in the percentage of plasma cells expressing CD45 with disease progression (Figure 2 ). There was a statistically significant difference in the percentage of plasma cells expressing CD45 between the group of patients CD45 expression in myeloma S Kumar et al with early disease (MGUS or SMM) and those with advanced disease (new or relapsed MM) (43 vs 22%; P ¼ 0.005). Among those with early disease, 69% were CD45 þ compared to 28% among those with advanced disease (P ¼ 0.0008).
Among the 46 patients with advanced disease, there was strong correlation between presence of lytic bone lesions on skeletal survey and percentage of plasma cells expressing CD45. The mean percentage of CD45 þ plasma cells was 14% (0.1-85) for those with bone lesions compared to 34% (2-99) for those with none; P ¼ 0.02. No significant correlation was found between the labeling index and CD45 expression. There was a negative correlation, between the total plasma cell percentage as determined on marrow biopsy and the percentage of plasma cells expressing CD45 (rho ¼ 0.314, P ¼ 0.04). High-grade angiogenesis was more commonly observed among those in the advanced group (58 vs 19%, P ¼ 0.002). Among those with advanced disease (n ¼ 46), patients with low-grade angiogenesis had a higher mean percentage of CD45 þ plasma cells; 31 vs 13% (P ¼ 0.03). A similar pattern was also seen among the MGUS/SMM where patients with low-grade angiogenesis had a mean of 50% CD45 þ plasma cells compared to 24% for those with high-grade angiogenesis (P ¼ NS). We also examined if there was a difference in the overall survival based on CD45 status, among those with advanced disease. There was a trend towards longer overall survival for the CD45 þ group (39 months) vs 18 months for the CD45À group (P ¼ 0.1) (Figure 3) .
The expression pattern for various adhesion molecules on the CD45 þ and CD45À plasma cells were examined (Figure 3 ). The expression of CD138 (syndecan-1), CD56 (NCAM) and CD54 (ICAM-1) were higher among the CD45À plasma cells. Other adhesion molecules, especially LFA-1, Mac-1, VLA-5 and CD44, were more often expressed on the CD45 þ plasma cells (Figure 4) . Given the previous reports of heterogeneity with in the CD45 þ cells based on CD49e expression, we examined if the proportion of CD45 þ CD49e þ and CD45 þ CD49eÀ cells had any relationship to the disease stage and did not find any significant differences. 17 
Discussion
Evaluation of the PCs in the bone marrow of myeloma patients clearly demonstrate two distinct groups of PCs based on CD45 expression À CD45 dim or negative and CD45 intermediate to bright. 3, 8, 18 During normal development, the marrow is populated predominantly by the CD45 þ population, which represents the early stage PCs. As they mature to terminally differentiated plasma cells, the CD45 expression is gradually lost. It is likely that the ratio of CD45 þ and CD45À population is maintained at a constant level, despite continuous maturation of PCs, by the ongoing apoptosis of terminally differentiated PCs. In contrast, we have demonstrated that in the marrow from patients with plasma cell proliferative disorders, the ratio of CD45 þ to CD45À plasma cells appears to be altered in relation to the disease stage. The early stages of plasma cell proliferative diseases, namely MGUS and SMM, are characterized by a nearly equal distribution of CD45 þ and CD45À PCs; whereas in newly diagnosed and relapsed MM, the CD45 population dominates. This is likely to be a result of decreased ongoing apoptosis among the terminally differentiated malignant PC population leading to accumulation of these cells. In fact, others have demonstrated an increase in the expression of antiapoptotic bcl2 protein in CD45À population. 3 We have previously also Median overall survival of patients with newly diagnosed and relapsed myeloma: Kaplan-Meier curve demonstrating the difference in overall survival between two groups of patients defined by the percentage of PCs expressing CD45.
Figure 4
Differential expression of different adhesion molecules on CD45 þ and CD45À plasma cells.
CD45 expression in myeloma
S Kumar et al demonstrated a reduced apoptotic index of myeloma marrow PCs compared to PCs from patients with MGUS. 19 Several other phenotypic and functional differences have been described between these two cell populations. The CD45 þ fraction appears to be the more proliferative fraction of myeloma cells. 20 These cells appear to be more responsive to IL-6 stimulation, an important growth factor for PCs in MM. 5, 7 IL-6 in turn appear to be capable of modulating the expression of CD45 on plasma cells. 7 Studies suggest that the interaction between CD45, which is a protein tyrosine phosphatase, and the src kinases (lyn, hck, lyk) may mediate this requirement for CD45 for the IL-6 signaling. 7 In this study, however, we could not demonstrate a correlation between labeling index and CD45 expression.
Our studies demonstrated a clear inverse relationship between the degree of bone marrow angiogenesis and the percentage of CD45 þ PCs. This finding is consistent with our previous data that showed a relationship between disease stage and marrow microvessel density. 16 However, even among those with advanced disease, there was a correlation between increased CD45À PCs and increased bone marrow microvessel density. Recent studies by Asosingh et al 21 using a 5T2MM murine model demonstrated an angiogenic switch that was preceded by a shift from CD45 þ to CD45À PCs. They were also able to demonstrate increased production of VEGF by the CD45À PCs compared to the CD45 þ cells. Clearly the CD45À PCs represent the more advanced 'malignant PC' capable of mediating the clinical manifestations of MM. This also explains the relationship we observed between the presence of bone lesions on the X-rays and the increased numbers of CD45À PCs. Differences in the chromosomal abnormalities have also been reported between the CD45À and CD45 þ PC populations. 18 Moreau et al 9 in a study of 95 patients with MM undergoing high-dose therapy demonstrated a shorter survival for patients lacking CD45 expression on plasma cells. In our study, among those with newly diagnosed or relapsed MM, there was a trend towards longer survival for the CD45 þ group; however, this difference was not significant, likely related to the small number of patients. Examination of the prognostic relevance of CD45 expression on marrow plasma cells will require study in a large group of new, untreated MM patients being treated on clinical trials where this parameter can be tested along with other known prognostic factors.
We also compared the expression of different adhesion molecules on the CD45 þ and CD45À cells. The expression of NCAM (CD56), ICAM-1 (CD54) and the b1 integrin (CD29) on the majority of the PCs is similar to previous reports. 22 CD19 and VLA2 were usually negative on PCs as expected. Loss of CD56 with disease progression has been demonstrated previously and is consistent with its predominant expression on the CD45À PCs. Similarly, CD138 a marker of late PCs is also expressed more often on the CD45À PCs. CD44 and CD11b has been reported to be expressed more often on the CD45 þ early stage PC precursors as we have seen in this study. 23 We demonstrated the presence of VLA6 (CD49f) in nearly half of the PCs and more frequently on CD45 þ cells; these results are at variance with those previously reported by Jensen et al. 23 Loss of CD11a and CD49e expression with disease progression has been reported before and is consistent with decreased expression of these antigens on the CD45À PCs. 24 These data are also consistent with the increased proliferation reported in cells expressing LFA1, 25 but is at variance with the increased proliferation reported with decreased CD49e expression. 26 In summary, we have correlated CD45 expression on bone marrow PCs with various clinical and pathological characteristics of myeloma. The degree of expression of CD45 on the myeloma cells has important clinical and biological correlates. In the context of MM, analysis of CD45 expression of PC populations appears to allow for categorization of disease stages. We present evidence favoring the loss of CD45 expression with disease progression resulting in two distinct groups of PCs in the bone marrow, which differ in their phenotypic and functional features. Predominant presence of CD45À PCs in the bone marrow indicates late stage of the disease and appears to portend a less favorable prognosis. Further studies are needed in order to characterize all the functional differences between these population and the factors associated with the progression. Modern techniques focusing at genomic and proteomic analyses of these tow subpopulations will shed new light on the disease biology and will result in identification of new targets for therapy.
